DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.

DDR inhibitors DNA damage response DNA repair glioma radiation therapy

Journal

Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420

Informations de publication

Date de publication:
22 Mar 2024
Historique:
medline: 21 5 2024
pubmed: 21 5 2024
entrez: 21 5 2024
Statut: aheadofprint

Résumé

DNA damage response (DDR) mechanisms are critical to maintenance of overall genomic stability, and their dysfunction can contribute to oncogenesis. Significant advances in our understanding of DDR pathways have raised the possibility of developing therapies that exploit these processes. In this expert-driven consensus review, we examine mechanisms of response to DNA damage, progress in development of DDR inhibitors in IDH-wild-type glioblastoma and IDH-mutant gliomas, and other important considerations such as biomarker development, preclinical models, combination therapies, mechanisms of resistance and clinical trial design considerations.

Identifiants

pubmed: 38770568
pii: 7678727
doi: 10.1093/neuonc/noae072
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Rifaquat Rahman (R)

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Diana D Shi (DD)

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Zachary J Reitman (ZJ)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.

Petra Hamerlik (P)

Division of Cancer Sciences, University of Manchester, Manchester, UK.

John F de Groot (JF)

Division of Neuro-Oncology, University of California San Francisco, San Francisco, California, USA.

Daphne A Haas-Kogan (DA)

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Alan D D'Andrea (AD)

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Erik P Sulman (EP)

Department of Radiation Oncology, New York University, New York, New York, USA.

Kirk Tanner (K)

National Brain Tumor Society, Newton, Massachusetts, USA.

Nathalie Y R Agar (NYR)

Department of Neurosurgery and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Jann N Sarkaria (JN)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Christopher L Tinkle (CL)

Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Ranjit S Bindra (RS)

Department of Therapeutic Radiology, Yale University, New Haven, Connecticut, USA.

Minesh P Mehta (MP)

Miami Cancer Institute, Baptist Hospital, Miami, Florida, USA.

Patrick Y Wen (PY)

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

Classifications MeSH